CAR-T

#Biotechnology #CAR-T #Flow Cytometry #Tumour #Webinar

Webinar: Imaging for target discovery for CAR T cell therapy

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It… Read More

#News #Trending News

#CAR-T #Cell therapy #Drug screening #Drug targets #Flow Cytometry #Tumour

How to assess the safety profile of potential CAR targets 

CAR T cell technology provides the foundation for established immunotherapies against certain types of blood cancer and holds great promise for the fight against many solid tumours too. One major drawback of conventional CAR T cell technology, which relies on a single target antigen, is the lack of tumour-associated antigens (TAAs) that… Read More

#News #Trending News

#CAR-T #DNA #Drug development #Drug discovery #Podcast #Synthetic biology

Podcast: Building on current drug discovery methods

This is the latest episode of the free DDW podcast, “Building on current drug discovery methods”. It covers two narrated article written for Volume 22, Issue 2 – Spring 2021 of DDW and read aloud by Megan Thomas. The articles are called “The new synthesis: How synthetic DNA technology is… Read More

#News #Trending News

#CAR-T #Flow Cytometry #Tumour #Webinar

How to identify and evaluate new tumour markers 

Major advances have been achieved in targeted immunotherapy with significant clinical benefits for patients. However, on-target/off-tumour toxicity is still a major concern, which highlights the clinical need for better targets to improve the safety profile of immunotherapies.   On-target/off-tumour toxicity is mainly based on the expression of tumour-associated… Read More

#News #Trending News

#Biotechnology #CAR-T #Tumour #Webinar

Using ultra high-content imaging for target discovery for CAR T cell therapy 

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It… Read More

#News #Trending News

#CAR-T #Cell and gene therapy #Collaboration #Drug development #Drug discovery

Sitting down with… Julian Cole, Cell & Gene Collective 

The Cell & Gene Collective publicly launched in May 2021. Lu Rahman caught up with Julian Cole, Country Medical Director of Gilead Sciences for the UK and Ireland to find out more about this cross-industry alliance between Astellas, bluebird bio, Bristol Myers Squibb, Kite (a Gilead company) and Novartis.  LR: What was… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#CAR-T #Oncology

Preclinical CAR T proof-of-concept data presented

Elicera Therapeutics, a Swedish clinical stage cell and gene therapy company that develops immuno-oncological treatments focusing on CAR T-cells and oncolytic viruses, has presented preclinical proof-of-concept data for the company’s iTANK-platform at the ESGCT (European Society of Gene & Cell Therapy) Virtual Congress 2021.  iTANK (immunoTherapies Activated with NAP for efficient… Read More

#News

#CAR-T #Cell therapy #GlobalData #Oncology #Tumour biology

Off-the-shelf potential for NK cell therapies for tumour treatment 

Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a range of cancers. Analysis of NK cell therapies, currently in development, reveals that 57% of these are allogeneic therapies, and although development in haematological indications is more advanced, there are a high number of therapies… Read More

#Cancer Research #News

#CAR-T #Cell therapy

Bioelectronic assays: Setting a standard for potency measurement

Bioelectronic assays allow scientists to precisely and continuously monitor cultured cells without labels or dyes. Dr Jim Ross, Chief Technology Officer and co-founder of Axion Biosystems, elaborates. Young industry, massive momentum Although cell-based immunotherapies for cancer treatment are relatively new, they are poised to take the biomedical world by storm. Read More

#Exclusive Content #News

#Biologics / Biotechnology #CAR-T #Cell therapy #Immunotherapy #Stem cells

Biotech’s pursuit of next-generation CAR-T

Listen to this article on the DDW Podcast: Pierre-Louis Joffrin leads Corporate Development at Mogrify. He examines immunotherapies including an assessment of the next generation of stem cell derived products. Biotech has joined the pursuit of next-generation CAR-Ts and it’s not subtle. Some new, others having pivoted towards the area, there… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Aptamers #CAR-T #Immunotherapy #Oncology

Research collaboration will develop bispecific agents for oncology

Ixaka and SomaLogic have created a research collaboration to support the development of aptamer-based bispecific therapeutics. The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer reagents (modified aptamers that bind tightly and specifically to protein targets) previously identified and screened by SomaLogic as potential candidates for combination with… Read More

#Cancer Research #News

#CAR-T #Drug discovery #Immuno-oncology #Immunotherapy #Institute of Cancer Research

Immune checkpoint inhibitors: What are the risks?

Immuno-oncology has advanced greatly through T cell-based therapeutic approaches (particularly immune checkpoint inhibitors). However, immune checkpoint inhibitors (ICIs) aren’t efficacious in all patients, and they carry risks. What are these risks? Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences speaks to Lu Rahman. Preclinical in vivo models serve as important… Read More

#Cancer Research #Exclusive Content #News

#Cancer research #CAR-T #Cell therapy #Drug development #Immuno-oncology

Innovation driving cell therapies toward the clinic

Sean Chang, Product Manager, Cell and Gene Therapy at Thermo Fisher Scientific It has been four years since the first Chimeric Antigen Receptor T-cell (CAR T) therapy drug, Kymriah1, was approved by the US Food and Drug Administration (FDA) for the treatment of B-cell acute lymphoblastic leukaemia (ALL). Since then,… Read More

#Exclusive Content #News

#CAR-T #Cell and gene therapy

Takara Bio agreement with BioNTech Cell & Gene Therapies

Takara Bio has entered into a License and Supply Agreement with BioNTech Cell & Gene Therapies. Takara Bio will grant BioNTech a commercial license to use applicable patents relating to RetroNectin, and will provide BioNTech with supplies of RetroNectin. The patented technologies licensed to BioNTech are based on Takara Bio’s… Read More

#News

#Biotherapeutics #Cancer research #CAR-T #Cell therapy #Clinical trials #Drug development

Aleta and Cancer Research UK to advance blood cancer therapy

Aleta Biotherapeutics and Cancer Research UK have collaborated to advance the early phase clinical development of Aleta’s CAR-T cell engager candidate, ALETA-001. Under the terms of the clinical development partnership, Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase I/IIa clinical trial of ALETA-001,… Read More

#News

#CAR-T #Oncology #Therapeutics

CAR T-cell therapy highly effective in patients with high-risk non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a Phase III clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. While… Read More

#Cancer Research #News #Videos